Update on epidemiological aspects of progressive supranuclear palsy

The cause of progressive supranuclear palsy (PSP), the most common form of the atypical parkinsonian disorders, is unknown. PSP is characterized by four‐repeat tau aggregates in neurons (neurofibrillary tangles) and glia in specific basal ganglia and brainstem areas. A thorough literature review led us to hypothesize that genetic and/or environmental factors contribute to its development. It is likely that inheritance of the H1/H1 tau genotype represents a predisposition to develop PSP requiring other environmental or genetic factors. Less likely, a relatively rare mutation with low penetrance could contribute to the abnormal tau aggregation present in this disorder. The possible role of chemicals in the diet or occupation, hypertension, traumatic brain injury, coffee, and inflammation or oxidative injury are reviewed. © 2003 Movement Disorder Society

[1]  S. Ohta,et al.  Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate , 1996, Neuroscience Letters.

[2]  M. Hallett,et al.  Research goals in progressive supranuclear palsy , 2000, Movement disorders : official journal of the Movement Disorder Society.

[3]  S. Ohta,et al.  A Novel and Neurotoxic Tetrahydroisoquinoline Derivative In Vivo: Formation of 1,3‐Dimethyl‐1,2,3,4‐Tetrahydroisoquinoline, a Condensation Product of Amphetamines, in Brains of Rats Under Chronic Ethanol Treatment , 1990, Journal of neurochemistry.

[4]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[5]  I Litvan,et al.  Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[6]  W. Kamphorst,et al.  Phenotypic variation in hereditary frontotemporal dementia with tau mutations , 1999, Annals of neurology.

[7]  R. Marconi,et al.  Smoking habits in multiple system atrophy and progressive supranuclear palsy , 2000, Neurology.

[8]  B. Hyman,et al.  Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. , 1999, Journal of neuropathology and experimental neurology.

[9]  L. Golbe Progressive supranuclear palsy in the molecular age , 2000, The Lancet.

[10]  J. Jankovic,et al.  Progressive supranuclear palsy and a multi‐infarct state , 1987, Neurology.

[11]  J. Kril,et al.  Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. , 2000, Archives of neurology.

[12]  R. Cody,et al.  Follow-up study of risk factors in progressive supranuclear palsy , 1996, Neurology.

[13]  E. Neafsey,et al.  Indole‐N‐Methylation of β‐Carbolines: The Brain's Bioactivation Route to Toxins in Parkinson's Disease? a, b , 1992, Annals of the New York Academy of Sciences.

[14]  T. Niwa,et al.  Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. , 1989, Journal of chromatography.

[15]  A. Lees,et al.  The clinical features and natural history of the Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1986, Neurology.

[16]  F. Mastaglia,et al.  Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome) clinical and electrophysiological observations in eleven cases. , 1973, Proceedings of the Australian Association of Neurologists.

[17]  E. Mccrank PSP risk factors , 1990, Neurology.

[18]  L. Golbe,et al.  Prevalence and natural history of progressive supranuclear palsy , 1988, Neurology.

[19]  K. Kikuchi,et al.  Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[20]  E. Beghi,et al.  Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis , 2001, Neurology.

[21]  M. Friedrich Pesticide study aids Parkinson research. , 1999, JAMA.

[22]  W. Kuhn,et al.  Elevated levels of harman and norharman in cerebrospinal fluid of Parkinsonian patients , 2005, Journal of Neural Transmission.

[23]  I Litvan,et al.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[24]  E. Mendez-Alvarez,et al.  Reduction of rat brain levels of the endogenous dopaminergic proneurotoxins 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydro-β-carboline by cigarette smoke , 2001, Neuroscience Letters.

[25]  C. Mariani,et al.  n-Hexane induces Parkinsonism in rodents , 1990, Brain Research.

[26]  K. Rabheru,et al.  Four Cases of Progressive Supranuclear Palsy in Patients Exposed to Organic Solvents* , 1989, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[27]  Posttraumatic akinetic‐rigid syndrome resembling Parkinson's disease: A report on three patients , 2000, Movement disorders : official journal of the Movement Disorder Society.

[28]  G. Schellenberg,et al.  A distinct familial presenile dementia with a novel missense mutation in the tau gene. , 1999, Neuroreport.

[29]  C. Goetz,et al.  Trauma and movement disorders. , 1992, Neurologic clinics.

[30]  M N Rossor,et al.  Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype , 2001, Neurology.

[31]  T. Nagatsu,et al.  An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.

[32]  D. Dickson,et al.  Microglial Activation Parallels System Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration , 2001, Journal of neuropathology and experimental neurology.

[33]  J. Olszewski,et al.  Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 1964 .

[34]  I Litvan,et al.  Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. , 2001, Archives of neurology.

[35]  J. Rogers,et al.  Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease , 1992, Neurology.

[36]  S. Croul,et al.  TGF-β receptors-I and -II immunoexpression in Alzheimer’s disease: a comparison with aging and progressive supranuclear palsy , 1998, Neurobiology of Aging.

[37]  E. Neafsey,et al.  Dopamine uptake inhibitory capacities of β-carboline and 3,4-dihydro-β-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products , 1990, Brain Research.

[38]  L. Thal,et al.  Clinical trials in Alzheimer disease: debate on the use of placebo controls. , 1999, Alzheimer disease and associated disorders.

[39]  T. Révész,et al.  Neuronal cytoskeletal changes are an early consequence of repetitive head injury , 1999, Acta Neuropathologica.

[40]  Jean-François Dartigues,et al.  Education and Risk for Alzheimer's Disease: Sex Makes a Difference EURODEM Pooled Analyses , 2000 .

[41]  I. Litvan,et al.  Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy , 2001, Neurology.

[42]  M. Tabaton,et al.  Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy , 2000, Annals of neurology.

[43]  M G Spillantini,et al.  Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. , 1999, Journal of neuropathology and experimental neurology.

[44]  A. Rajput,et al.  Progressive Supranuclear Palsy , 2001, Drugs & aging.

[45]  S. Ohta,et al.  Novel Endogenous 1,2,3,4‐Tetrahydroisoquinoline Derivatives: Uptake by Dopamine Transporter and Activity to Induce Parkinsonism , 1998, Journal of neurochemistry.

[46]  G. Schellenberg,et al.  A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L) , 1999, Brain : a journal of neurology.

[47]  I Litvan,et al.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy. , 1999, Human molecular genetics.

[48]  N. Mantel,et al.  Geographic patterns of parkinsonism-dementia complex on Guam. 1956 through 1985. , 1990, Archives of neurology.

[49]  T. Niwa,et al.  Detection of tetrahydroisoquinoline in parkinsonian brain as an endogenous amine by use of gas chromatography-mass spectrometry. , 1989, Journal of chromatography.

[50]  S. Ohta,et al.  Presence of tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline in foods: compounds related to Parkinson's disease. , 1988, Life sciences.

[51]  K. Flanders,et al.  Transforming Growth Factor-β: Neuronal and Glial Expression in CNS Degenerative Diseases , 1995 .

[52]  I Litvan,et al.  Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias , 1999, Neurology.

[53]  N. Mantel,et al.  Patterns of acquiring parkinsonism-dementia complex on Guam. 1944 through 1985. , 1990, Archives of neurology.

[54]  M. Goedert,et al.  Tau protein pathology in neurodegenerative diseases , 1998, Trends in Neurosciences.

[55]  M. Nefzger,et al.  A retrospective study of smoking in Parkinson's disease. , 1968, American journal of epidemiology.

[56]  C. DeCarli,et al.  Head injury and the risk of AD in the MIRAGE study , 2000, Neurology.

[57]  C. Tanner,et al.  Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.

[58]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.

[59]  Y. Lapierre Pharmacological therapy of dysthymia , 1994, Acta psychiatrica Scandinavica. Supplementum.

[60]  G. Schellenberg,et al.  Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.

[61]  M. Pericak-Vance,et al.  Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease , 1996, The Lancet.

[62]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[63]  T. Niwa,et al.  Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. , 1988, Journal of chromatography.

[64]  D. Maraganore,et al.  Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990 , 1997, Neurology.

[65]  E. Neafsey,et al.  Differential Cytotoxicities of N‐Methyl‐β‐Carbolinium Analogues of MPP+ in PC12 Cells: Insights into Potential Neurotoxicants in Parkinson's Disease , 1994, Journal of neurochemistry.

[66]  J. Bogousslavsky,et al.  Presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy. , 1997, Archives of neurology.

[67]  P. Laippala,et al.  Head injuries and cognitive decline among older adults , 1999, Neurology.

[68]  K. Hirayama,et al.  Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy , 1994, Acta neurologica Scandinavica.

[69]  I Litvan,et al.  Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders , 1996, Journal of neuropathology and experimental neurology.

[70]  A. Hofman,et al.  Rates and risk factors for dementia and Alzheimer’s disease , 1999, Neurology.

[71]  M. Diamond,et al.  Enriching Heredity: The Impact of the Environment on the Anatomy of the Brain , 1988 .

[72]  S. Ohta,et al.  1‐Methyl‐ 1,2,3,4‐Tetrahydroisoquinoline, Decreasing in 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Treated Mouse, Prevents Parkinsonism‐Like Behavior Abnormalities , 1991, Journal of neurochemistry.

[73]  G. Schellenberg,et al.  Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. , 1997, American journal of epidemiology.

[74]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[75]  Y Ben-Shlomo,et al.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study , 1999, The Lancet.

[76]  E. Kokmen,et al.  Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. , 1999, American journal of epidemiology.

[77]  A. Ludolph,et al.  Slow toxins, biologic markers, and long‐latency neurodegenerative disease in the western Pacific region , 1991, Neurology.

[78]  G. Pezzoli,et al.  PARKINSONISM DUE TO n-HEXANE EXPOSURE , 1989, The Lancet.

[79]  D. Maraganore,et al.  Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[80]  I Litvan,et al.  Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination , 1998, Journal of neurology, neurosurgery, and psychiatry.

[81]  J. Silverman,et al.  A case‐control study of Alzheimer's disease in China , 1992, Neurology.

[82]  A. Delacourte,et al.  Neurofibrillary Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration , 1999, Journal of neurochemistry.

[83]  E. Neafsey,et al.  Striatal dopaminergic toxicity following intranigral injection in rats of 2-methyl-norharman, a β-carbolinium analog of N-methyl-4-phenylpyridinium ion (MPP+) , 1989, Neuroscience Letters.

[84]  D. Maraganore,et al.  Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.

[85]  J. Troncoso,et al.  Overexpression of four‐repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease , 1999, Annals of neurology.

[86]  S. Ohta,et al.  Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter. , 1998, European journal of pharmacology.

[87]  J. Langston,et al.  Parkinsonism caused by petroleum waste ingestion , 1994, Neurology.

[88]  J. Jankovic,et al.  Vascular progressive supranuclear palsy. , 1994, Journal of neural transmission. Supplementum.

[89]  Alexis Elbaz,et al.  Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study , 1999, The Lancet.

[90]  G. Schellenberg,et al.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[91]  P. Lantos,et al.  Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.

[92]  S. Ohta,et al.  1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF , 1995, Journal of neurochemistry.

[93]  J. Dambrosia,et al.  Environmental— occupational risk factors and familial associations in multiple system atrophy: A preliminary investigation , 1991, Clinical Autonomic Research.

[94]  L. Golbe,et al.  Risk factors for progressive supranuclear palsy , 1988, Neurology.

[95]  K. Beyreuther,et al.  Bcl‐xl‐Specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states , 1997, Journal of neuroscience research.

[96]  P. Satz Brain reserve capacity on symptom onset after brain injury: A formulation and review of evidence for threshold theory. , 1993 .

[97]  Claire Shepherd,et al.  Alzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms , 2000, Clinical and experimental pharmacology & physiology.

[98]  E. Neafsey,et al.  Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. , 1990, Brain research.

[99]  C. Colosimo,et al.  Presymptomatic Hypertension in Progressive Supranuclear Palsy , 1998 .

[100]  T. Niwa,et al.  Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.

[101]  I. Mackenzie,et al.  Positive CSF HSV PCR in patients with GBM: A note of caution , 2000, Neurology.

[102]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[103]  D. Burn,et al.  The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. , 2001, Brain : a journal of neurology.

[104]  A. Hofman,et al.  Head trauma and risk of dementia and Alzheimer’s disease , 1999, Neurology.

[105]  J. P. Brandel,et al.  Accuracy of the Clinical Diagnosis of Corticobasal Degeneration , 1997, Neurology.